Although cisplatin remains the most active drug used to treat ovarian cancer, ironically a majority of patients who initially respond to the treatment, eventually succumb to the disease. Arsenic is now making headlines among cancer research, as it has the potential to help overcome platinum resistance. It is an exciting agent that has already demonstrated its safety profile by clinically treating promyelocytic leukemia, which is a type of blood cancer. In addition, arsenic is showing promise in destroying ovarian cancer cells, as well as enhancing the activity of cisplatin. It is without a doubt that further clinical trial assessments can reveal the true benefits of this agent in the treatment of several type of cancers, including ovarian cancer, breast cancer, and other refractory cancers.